BioAdaptives Inc. BDPT Archives

ThursdayJul 23, 2026 9:00 am

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) Completes Manufacturing Readiness for Wellness Product Launch

BioAdaptives (OTC: BDPT) a developer of science-driven wellness products, announced it has completed commercial manufacturing and logistics supply chain readiness, positioning the company to begin rolling out its next-generation wellness platforms next month. The company said it spent the past quarter securing standardized raw materials and partnering with GMP-compliant manufacturing facilities to support anticipated demand for its MyndSystem(TM) cognitive performance platform and upcoming Xcellara(TM) cellular wellness products. BioAdaptives (OTC: BDPT) said its dual-platform strategy targets growing global wellness markets through the stimulant-free, WADA-compliant MyndSystem(TM), designed to support cognitive performance during the day and neurological recovery overnight, and the Xcellara(TM) platform,…

WednesdayJul 15, 2026 9:20 am

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) Announces Aug. 1 Launch of XcellaraHeart Cardiovascular Wellness Supplement

BioAdaptives (OTC: BDPT) announced the upcoming commercial launch of XcellaraHeart(TM), a cardiovascular wellness supplement that combines the company's Xcellara(TM) stem/progenitor cell mobilization formula with Tanshinone IIA, a bioactive compound derived from Danshen root. The company said the Xcellara(TM) base is supported by a randomized, double-blind, placebo-controlled clinical trial that demonstrated an average 268.8% increase in circulating primitive stem/progenitor-type cells after four weeks, while Tanshinone IIA has been studied for its effects on the SDF-1α/CXCR4 signaling pathway associated with cellular trafficking and cardiovascular repair biology. XcellaraHeart(TM) is scheduled to be available for order beginning Aug. 1, 2026, with initial deliveries expected…

TuesdayApr 28, 2026 10:10 am

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTCMKTS: BDPT) Launches MyndMed Cognitive-Support Supplement Following Successful Testing and Strong Early Demand

BioAdaptives (OTCMKTS: BDPT) announced the commercial launch of MyndMed(TM), a next-generation dietary supplement designed to enhance memory, focus, and overall brain performance. Following extensive testing with highly positive user feedback, the company is scaling production and expanding distribution to meet anticipated high demand beginning in November. Formulated to support cognitive function across short-, mid-, and long-term pathways, MyndMed(TM) delivers what the company calls “Mental Armor for Modern Minds(TM)” through clinically studied ingredients that promote alertness, neuroplasticity, and cellular energy balance. Manufactured in the U.S. in cGMP-certified facilities and third-party tested for purity, MyndMed(TM) is available nationwide at www.MyndMed.com. To view…

TuesdayOct 07, 2025 11:55 am

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTCMKTS: BDPT) Launches MyndMed Cognitive-Support Supplement Following Successful Testing and Strong Early Demand

WednesdayJul 16, 2025 9:30 am

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC Pink: BDPT) Prepares for National Launch of NeuroRush(TM) Nootropic in Late Summer 2025

BioAdaptives (OTC Pink: BDPT), a wellness innovator, announced the national rollout of NeuroRush(TM), its next-generation nootropic aimed at enhancing mental clarity, cognitive endurance, and stress adaptability. Following strong results in test markets, the adaptogen-based formula will launch in August/September 2025 in two versions—one with natural caffeine and one caffeine-free. Formulated with clinically studied ingredients like Rhodiola, Ashwagandha, and Bacopa, NeuroRush(TM) supports brain health without the crash of stimulants. The product will be available online and through strategic wellness partners. To view the full press release, visit https://ibn.fm/R0VE2 About BioAdaptives, Inc. BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the…

TuesdayJun 24, 2025 10:45 am

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC Pink: BDPT) to Launch Pawpa(TM) Regen Nationwide as Stem Cell-Based Canine Supplement Gains Momentum

BioAdaptives (OTC Pink: BDPT), a leader in nutraceutical and wellness innovation, will launch its proprietary canine supplement Pawpa(TM) Regen nationwide by the end of July 2025. Designed to support natural stem cell activation in aging dogs, the supplement has shown promising results in early trials, including improved energy, mobility, coat quality, and temperament. CEO James Keener emphasized the product’s unique regenerative approach using safe, naturally sourced ingredients. With strong early feedback and growing demand for holistic pet care solutions, BioAdaptives is expanding production ahead of the broader e-commerce rollout. To view the full press release, visit https://ibn.fm/Y6PRK About BioAdaptives, Inc.…

WednesdayMay 28, 2025 11:35 am

QualityStocksNewsBreaks – Bioadaptives Inc (BDPT) Showcases Breakthrough Stem Cell Benefits in Regen Dog Chews

Bioadaptives (BDPT), through its premium pet wellness division PawPa(TM), announced compelling clinical results for its flagship product Regen(TM) Dog Chews, formulated to naturally stimulate stem cell release and support canine vitality, mobility, and comfort. In veterinarian-led trials, Regen demonstrated a 281.3% increase in circulating stem cells after four weeks. The product's benefits are further measured using the company’s proprietary APBAR(R) rating system—modeled after the human APGAR score—helping pet owners track improvements in appearance, performance, behavior, attitude, and responsiveness. Crafted with all-natural ingredients including beneficial cyanobacteria and adaptogens, Regen(TM) is veterinarian-recommended, safe, and delivered in a tasty chew dogs love. With…

ThursdayMar 13, 2025 9:25 am

QualityStocksNewsBreaks – Bioadaptives Inc (BDPT) Completes Successful Dosage Trials for Zeranovia™ Weight Loss Product

Bioadaptives (BDPT) announced the successful completion of dosage trials for Zeranovia™, its innovative weight loss product. Participants in the trial reported consistent weight loss of 5 to 7 pounds per week with minimal side effects, primarily mild gastrointestinal discomfort that was managed through dosage adjustments. With high participant satisfaction and all subjects eager to continue, BioAdaptives plans to refine dosing for the next phase of clinical trials, reinforcing its commitment to providing effective weight management solutions. To view the full press release, visit https://ibn.fm/Ho0gx About BioAdaptives, Inc. BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the health and wellness…

ThursdayFeb 06, 2025 1:40 pm

QualityStocksNewsBreaks – BioAdaptives Inc. (BDPT) Announces Board Appointment of UFC Senior Executive Reed Harris

BioAdaptives (OTC: BDPT), a leading biotechnology company focused on innovative health and wellness solutions, has announced the appointment of Reed Harris to its board of advisors. Harris, the senior VP of athlete development and marketing at the Ultimate Fighting Championship (“UFC”) in Las Vegas, brings decades of experience in leadership, athlete development and business management, as well as a proven commitment to driving innovation and excellence. “Reed’s exceptional leadership, business acumen and dedication to athlete development and community service align perfectly with our mission to deliver innovative health and wellness solutions,” said Jim Keener, CEO of BioAdaptives. “His deep experience…

TuesdayDec 10, 2024 1:40 pm

QualityStocksNewsBreaks – BioAdaptives Inc. (BDPT) Launches Xcellara(TM) — an Innovative Supplement That Harnesses Nature for Optimal Health

BioAdaptives (OTC: BDPT) today announced the launch of Xcellara(TM) Stem Cell Activator, a groundbreaking supplement that harnesses the extraordinary potential of stem cells' regeneration power through a blend of adaptogens, herbs and beneficial bacteria. The innovative formulation supports the body's natural repair mechanisms, promoting anti-aging and enhancing overall health and wellness. "This is an exciting milestone for BioAdaptives as we continue to push the boundaries of what's possible in natural health supplements," said the company’s CEO James Keener. "With the launch of Xcellara(TM) Stem Cell Activator, we're offering a product that's both innovative and deeply rooted in science, leveraging a…

Site Search

Company Search

Tag: BioAdaptives Inc. BDPT

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) Completes Manufacturing Readiness for Wellness Product Launch

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC: BDPT) Announces Aug. 1 Launch of XcellaraHeart Cardiovascular Wellness Supplement

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTCMKTS: BDPT) Launches MyndMed Cognitive-Support Supplement Following Successful Testing and Strong Early Demand

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTCMKTS: BDPT) Launches MyndMed Cognitive-Support Supplement Following Successful Testing and Strong Early Demand

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC Pink: BDPT) Prepares for National Launch of NeuroRush(TM) Nootropic in Late Summer 2025

QualityStocksNewsBreaks – BioAdaptives, Inc. (OTC Pink: BDPT) to Launch Pawpa(TM) Regen Nationwide as Stem Cell-Based Canine Supplement Gains Momentum

QualityStocksNewsBreaks – Bioadaptives Inc (BDPT) Showcases Breakthrough Stem Cell Benefits in Regen Dog Chews

QualityStocksNewsBreaks – Bioadaptives Inc (BDPT) Completes Successful Dosage Trials for Zeranovia™ Weight Loss Product

QualityStocksNewsBreaks – BioAdaptives Inc. (BDPT) Announces Board Appointment of UFC Senior Executive Reed Harris

QualityStocksNewsBreaks – BioAdaptives Inc. (BDPT) Launches Xcellara(TM) — an Innovative Supplement That Harnesses Nature for Optimal Health

Market Basics

Newsletter Publishers

Public Companies